Menu
M. Alexander Shaw appointed CEO of Prolifagen Therapeutics. Learn more here.
Prolifagen recently won an award at the M2D2 200K challenge. Learn more here.
Deep Tech Pioneers
Among 5,000 applicants from 128 different countries, Prolifagen has been selected as one of @hello tomorrow’s Deep Tech Pioneers from their annual Global Challenge! Come and meet us at the virtual Hello Tomorrow Global Summit on 16th-20th November, 2020!
OUR MISSION
Prolifagen is a preclinical spin-out of University of Pennsylvania developing a medicine for cardiac regeneration based on microRNA technology.
Our management team holds essential complementary skill sets in differing areas of domain expertise and bring decades of experience to this work.
microRNA 302 drives proliferation of resident adult cardiac muscle cells in injured hearts, leading to reconstitution of functional heart muscle.